Emory University’s Abiomed Inc ABMD Stock Holding History

Emory University’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-7,065	Closed	-$2.89M	–	50
2018 Q2	$2.89M	Buy	+7,065	New	+$2.56M	1.92%	8

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Emory University's ABMD Position: Q3 2018 in Review

Emory University sold out of Abiomed Inc (ABMD) in Q3 2018, closing a stake of 7,065 shares — an estimated $2.89M sold.

Emory University first reported a position in ABMD in Q2 2018 and held it in 1 quarter. The position peaked at $2.89M in Q2 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q3 2018.

Emory University reported no remaining Abiomed Inc position as of Q3 2018 after selling out during the quarter.
Emory University sold 7,065 Abiomed Inc shares in Q3 2018, an estimated $2.89M.
Emory University first reported a position in Abiomed Inc in Q2 2018 and held it in 1 quarter.
Emory University's Abiomed Inc position peaked at $2.89M in Q2 2018.
529 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2018.

Based on Emory University's 13F filing for Q3 2018, filed 14 Nov 2018.